Physician profile
Michael J Eckrich
NPI 1194918631
$54,729.21
in general payments reported to CMS, 2019-2025
7 companies · $12K in 2025
The $12K reported for 2025 was more than what 87% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2021: $616 · 2022: $3,638 · 2023: $7,744 · 2024: $30K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $3,787 · Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,728.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,225.00 |
| Travel and Lodging | $3,787.20 |
| Food and Beverage | $1,703.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $47,532.93 | 2021-2025 | |
| Y-Mabs Therapeutics, INC. | $5,279.11 | 2024 | Danyelza |
| Novartis Pharmaceuticals Corporation | $1,069.26 | 2019-2025 | Kymriah |
| Jazz Pharmaceuticals INC. | $377.57 | 2019-2025 | |
| Medexus Pharma, INC. | $222.98 | 2025 | Grafapex |
| Sanofi-Aventis U.S. LLC | $148.36 | 2024 | |
| Astellas Pharma US INC | $99.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eckrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.